Acorda Therapeutics (ACOR) says a proof-of-concept trial shows AMPYRA, the company's FDA...

|About: Acorda Therapeutics, Inc. (ACOR)|By:, SA News Editor

Acorda Therapeutics (ACOR) says a proof-of-concept trial shows AMPYRA, the company's FDA approved walking treatment for multiple sclerosis, also improves walking in patients with post-stroke deficits. ACOR says once it has completed its analysis it will consult with the FDA on developing the drug for use by stroke survivors. Shares +8.6% premarket.